Should treatment recommendations for lipid lowering drugs be based on absolute coronary risk or risk reduction?

BMJ

Volumn 320, Issue 7236, 2000, Pages 677-679

  Ramachandran, S ^a   French, J M ^b   Vanderpump, M P J ^c   Croft, P ^a   Neary, R H ^a  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CALCULATION; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; FEMALE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; STATISTICAL MODEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTILIPEMIC AGENTS; CORONARY DISEASE; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; REFERENCE VALUES; RISK ASSESSMENT;

EID: 0034635819     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.320.7236.677     Document Type: Article

References (5)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307.
2. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol lower risk of ischaemic heart disease? BMJ 1994; 308: 367–372.
3. West of Scotland Coronary Prevention Group. West of Scotland coronary prevention study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339–1342.
4. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary heart disease. Br Med Bull 1994; 50: 272–298.
5. Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233–241.